2020 review – Pharma’s progress outside of COVID-19
pharmaphorum
DECEMBER 23, 2020
There was some steady progress in neurology – in February FDA approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs from a new class. Pharma companies have also made headway in rare diseases as several pipeline projects came to fruition. months, compared with 6.7
97 
Let's personalize your content